AbbVie

Mentioned in 7 analyzed podcast episodes across 7 shows

Mentioned On

Latent Space: The AI Engineer Podcast Wall Street Breakfast BioSpace Vital Dawn Pharma and BioTech Daily Motley Fool Money Squawk Pod

Episode Mentions

Latent Space: The AI Engineer Podcast · Jul 16, 2026

🔬 The Lab of the Future Should Feel Like a Data Center — Andy Beam & Rafa Gómez-Bombarelli, Lila Sciences

“Acquired Capstan Therapeutics for $2.1B for in vivo CAR-T technology; benchmark for Lila's CAR-T work”

Reinforcement Learning for Scientific DiscoveryLab Automation and Robotics IntegrationAI Safety in Autonomous Experimentation

View Analysis

Wall Street Breakfast · Jul 12, 2026

Earnings, inflation take center stage

“Going ex-dividend Wednesday with payment on August 14th”

Q2 Bank Earnings SeasonAI Spending and Demand SignalsSemiconductor Equipment Guidance

View Analysis

BioSpace · May 13, 2026

Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

“CEO Robert Hugin among top-paid executives; one of three Roberts leading major pharma companies”

FDA Commissioner leadership transition and removalRegulatory uncertainty and HHS agency turnoverCommissioner's National Priority Review voucher program

View Analysis

Vital Dawn · Apr 29, 2026

Vital Dawn Podcast for Wednesday April 29

“Large-cap pharmaceutical company reporting earnings before market open on April 29th”

Q1 2024 Earnings Season Peak VolumeSemiconductor Industry AI Demand TrendsConsumer Spending Resilience

View Analysis

Pharma and BioTech Daily · Apr 24, 2026

Regeneron Gene Therapy Approved by FDA: A Game-Changer! | Pharma and Biotech Daily

“Announced $1.4 billion investment in North Carolina to establish new pharmaceutical production base”

Gene Therapy Regulation and FDA Approval PathwaysHearing Loss Treatment InnovationGLP-1 Receptor Agonists for Type 2 Diabetes

View Analysis

Motley Fool Money · Apr 12, 2026

The Psychedelic Revolution

“Acquired Gail Gomesh in August for psychedelic compound aladicicin, signaling Big Pharma's early strategic positioning”

Psychedelic-Assisted Therapy Clinical EfficacyTreatment-Resistant Depression Market OpportunityFDA Approval Pathways for Psychedelic Compounds

View Analysis

Squawk Pod · Jan 9, 2026

5 Things to Know Before the Opening Bell 1/9/26

“Denied Wall Street Journal report that it was in talks to acquire RevMed”

Pharmaceutical M&A and Industry ConsolidationCancer Drug Development and AcquisitionFitness Tracking Technology IPOs

View Analysis